FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308380060> ?p ?o ?g. }

• W4308380060 abstract "<h3>Background</h3> Canonical tumor surface PDL1 signals to PD1 on immune cells to evade antitumor immunity are well-defined.¹ However, tumor-intrinsic PDL1 mediates additional pathologic signals.^2-5 Our lab recently showed that tumor PDL1 promotes homologous recombination DNA damage repair and ATM/Chk2 DNA damage sensing. Genetic tumor PDL1 depletion rendered tumors sensitive to Chk1 and PARP inhibitors.^{6, 7} However, anti-PDL1 antibodies were unable to replicate treatment sensitivity,⁶ and genetic PDL1 depletion is not yet clinically feasible. We hypothesized that pharmacologic tumor PDL1 depletion could replicate genetic PDL1 depletion to sensitize tumors to therapy as a translational application of tumor PDL1 depletion. <h3>Methods</h3> We conducted a high-throughput drug screen enriched for FDA-approved molecules in RFP-PDL1 B16 cells to identify PDL1 depleting drugs (PDDs).⁸ B16 cells were treated with 2.5 or 10 mM of screen drug for 48 hours, and RFP intensity was measured by fluorescence. We use various biochemical, cell biology, and genetic techniques to interrogate <i>in vitro</i> PDD mechanisms and <i>in vivo</i> studies of treatment and immune outcomes using human and transplantable murine cell lines of distinct cancers. <h3>Results</h3> We identified the FDA-approved, structurally similar cephalosporin antibiotics cefepime and ceftazidime and the alkylating agent chlorambucil as PDDs with distinct signaling and treatment consequences. Cefepime and ceftazidime potently depleted PDL1 in several tumor lines and phenocopied genetic PDL1 depletion by inducing DNA damage and significantly depleting Chk2 protein. Cefepime and ceftazidime PDL1-dependently generated synthetic lethality to small molecule Chk1 inhibitors <i>in vitro</i>, and cefepime generated Chk1 inhibitor efficacy <i>in vivo</i>. Other beta-lactams failed to deplete PDL1, suggesting the beta-lactam ring is dispensable for PDL1 depletion. Cefepime and ceftazidime replicated additional genetic PDL1 depletion outcomes, including STING and autophagy induction and tumor stemness reduction <i>in vitro</i>. Cefepime induced an immune Th1 signature <i>in vivo</i> in tumor-bearing mice, consistent with STING induction and suggesting PDDs could improve immunotherapy efficacy. Strikingly, the PDD chlorambucil potently depleted ovarian cancer PDL1 and induced anti-PDL1 efficacy in PDL1-replete, anti-PDL1-resistant tumors through an NK-dependent mechanism. These data suggest tumor immunogenicity consequences of chlorambucil-mediated tumor PDL1 depletion. <h3>Conclusions</h3> PDDs induce novel cancer treatment vulnerabilities with high clinical translational potential. We identify several FDA-approved drugs that deplete tumor PDL1, disrupt its pathogenic tumor-intrinsic signals, and induce small molecule synthetic lethality and anti-PDL1 efficacy improvement. We identified other PDDs offering opportunities as translational targets, which we are now progressing to phase I clinical trials. <h3>Acknowledgements</h3> This research was funded by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant TL1 TR002647 (C.M.) and the NIH T32GM113896 (STX MSTP) Award (C.M.). The Clayton Foundation (no grant number) and the NCI (CA204965, CA054515) supported T.C. Flow cytometry data were generated at the UT Health San Antonio Flow Cytometry Shared Resource Facility, supported by the National Center for Advancing Translational Sciences, National Institutes of Health through Grant UL1 TR002645. <h3>References</h3> Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K <i>et al</i>. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. <i>Nat Med</i>. 2002; <b>8</b>(8):793–800. Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K <i>et al</i>. Tumor-Intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. <i>Cancer Res</i>. 2016; <b>76</b>(23):6964–6974. Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, Hurez V, Conejo-Garcia J, Vadlamudi R, Li R <i>et al</i>. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. <i>Signal Transduct Target Ther</i>. 2016; 1. Zhang D, Reyes RM, Osta E, Kari S, Gupta HB, Padron AS, Kornepati AVR, Kancharla A, Sun X, Deng Y <i>et al</i>. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. <i>Cancer Med</i>. 2021; <b>10</b>(6):2137–2152. Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. <i>Nat Rev Cancer</i>. 2022; <b>22</b>(3):174–189. Kornepati AVR, Boyd JT, Murray CE, Saifetyarova J, de la Pena Avalos B, Rogers CM, Bai H, Padron AS, Liao Y, Ontiveros C <i>et al</i>. Tumor-intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality. <i>Cancer Res</i>. 2022; <b>82</b>(11): 2156–2170. Anand Kornepati, Clare Murray, Barbara Avalos, Cody Rogers, Kavya Ramkumar, Harshita Gupta, Yilun Deng, Zexuan Liu, Alvaro Padron, Ratna Vadlamudi, Eloise Dray, Weixing Zhao, Patrick Sung, Lauren Byers, Tyler Curiel. Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner. <i>J. Immunother. Cancer</i>. 2021; <b>9</b>(2):A944. Murray C, Galvan E, Ontiveros C, Deng Y, Bai H, Padron AS, Hinchee-Rodriguez K, Garcia MG, Kornepati A, Conejo-Garcia J <i>et al</i>. Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents. <i>Int J Mol Sci</i>. 2022; <b>23</b>(9). <h3>Ethics Approval</h3> All animal studies were approved by the UT Health San Antonio Institutional Animal Care and Use Committee (Number 09128)." @default.
• W4308380060 created "2022-11-11" @default.
• W4308380060 creator A5018054590 @default.
• W4308380060 creator A5044217766 @default.
• W4308380060 creator A5045824377 @default.
• W4308380060 creator A5055103607 @default.
• W4308380060 creator A5066458124 @default.
• W4308380060 creator A5070479090 @default.
• W4308380060 creator A5074770263 @default.
• W4308380060 creator A5079368617 @default.
• W4308380060 creator A5087167137 @default.
• W4308380060 date "2022-11-01" @default.
• W4308380060 modified "2023-10-16" @default.
• W4308380060 title "453 Pharmacologic tumor PDL1 depletion as a translational approach to inhibit tumor-intrinsic PDL1 signals and create novel treatment vulnerabilities" @default.
• W4308380060 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0453" @default.
• W4308380060 hasPublicationYear "2022" @default.
• W4308380060 type Work @default.
• W4308380060 citedByCount "0" @default.
• W4308380060 crossrefType "proceedings-article" @default.
• W4308380060 hasAuthorship W4308380060A5018054590 @default.
• W4308380060 hasAuthorship W4308380060A5044217766 @default.
• W4308380060 hasAuthorship W4308380060A5045824377 @default.
• W4308380060 hasAuthorship W4308380060A5055103607 @default.
• W4308380060 hasAuthorship W4308380060A5066458124 @default.
• W4308380060 hasAuthorship W4308380060A5070479090 @default.
• W4308380060 hasAuthorship W4308380060A5074770263 @default.
• W4308380060 hasAuthorship W4308380060A5079368617 @default.
• W4308380060 hasAuthorship W4308380060A5087167137 @default.
• W4308380060 hasBestOaLocation W43083800601 @default.
• W4308380060 hasConcept C102744134 @default.
• W4308380060 hasConcept C143425029 @default.
• W4308380060 hasConcept C203014093 @default.
• W4308380060 hasConcept C207001950 @default.
• W4308380060 hasConcept C2777701055 @default.
• W4308380060 hasConcept C502942594 @default.
• W4308380060 hasConcept C54355233 @default.
• W4308380060 hasConcept C552990157 @default.
• W4308380060 hasConcept C86803240 @default.
• W4308380060 hasConcept C8891405 @default.
• W4308380060 hasConceptScore W4308380060C102744134 @default.
• W4308380060 hasConceptScore W4308380060C143425029 @default.
• W4308380060 hasConceptScore W4308380060C203014093 @default.
• W4308380060 hasConceptScore W4308380060C207001950 @default.
• W4308380060 hasConceptScore W4308380060C2777701055 @default.
• W4308380060 hasConceptScore W4308380060C502942594 @default.
• W4308380060 hasConceptScore W4308380060C54355233 @default.
• W4308380060 hasConceptScore W4308380060C552990157 @default.
• W4308380060 hasConceptScore W4308380060C86803240 @default.
• W4308380060 hasConceptScore W4308380060C8891405 @default.
• W4308380060 hasLocation W43083800601 @default.
• W4308380060 hasOpenAccess W4308380060 @default.
• W4308380060 hasPrimaryLocation W43083800601 @default.
• W4308380060 hasRelatedWork W1495914562 @default.
• W4308380060 hasRelatedWork W1562559317 @default.
• W4308380060 hasRelatedWork W2014403601 @default.
• W4308380060 hasRelatedWork W2099588420 @default.
• W4308380060 hasRelatedWork W2134440723 @default.
• W4308380060 hasRelatedWork W2908348540 @default.
• W4308380060 hasRelatedWork W3007075535 @default.
• W4308380060 hasRelatedWork W3141480656 @default.
• W4308380060 hasRelatedWork W4224077265 @default.
• W4308380060 hasRelatedWork W4241494942 @default.
• W4308380060 isParatext "false" @default.
• W4308380060 isRetracted "false" @default.
• W4308380060 workType "article" @default.